Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision

Conclusions The baseline BCVA–LLVA gap is a significant predictor of visual acuity response to anti-VEGF treatment in patients with wAMD. Trial registration number NCT00891735; Post-results.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Retina, Open access Original articles - Clinical science Source Type: research